Does measuring high-sensitivity cardiac troponin I before rather than after each treatment cycle more reliably detect cardiotoxicity in breast cancer patients receiving anthracycline therapy?
High-sensitivity cardiac troponin I should be measured before rather than after anthracycline treatment cycles to most reliably detect early cardiotoxicity in breast cancer patients.
Cardiotoxicity arising from anthracycline therapy is detectable in the earliest stages of breast cancer treatment and is cumulative with each treatment cycle. This injury is most reliably determined from blood sampling carried out before rather than after each treatment cycle.
Tzolos et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: